CAR T-Cell Therapy Granted Priority Review for DLBCL – Cancer Network
CAR T-Cell Therapy Granted Priority Review for DLBCLCancer NetworkOther CAR T-cell therapies approved in 2017 include tisagenlecleucel for the treatment of children and young adults up to 25 years of age with relapsed or refractory B-cell precursor acu… Continue reading
